Pura Vida Investments
VC Fund
New York, United States
Pura Vida Investments is a fundamentally driven, market neutral healthcare-focused investment vehicle. The objective of the firm is to identify and capitalize on structural changes in the healthcare landscape and on inflections in company specific valuations. The firm strives to look past day-to-day volatility and to hone in on major value shiftsover the medium to longer term.The firm’s portfolio is managed by Efrem Kamen and Doron Junger MD and is run in a market neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences and healthcare services. The Fund has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 3%
- Fund size:
- $5.1M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pura Vida Investments invests in
Stages Pura Vida Investments invests in
Countries Pura Vida Investments invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Efrem Kamen
|
|||
Frank Litvack
|
|||
Frank Litvack
|
|||
Investment Focus
Industry
- Health Care 21 (53%)
- Biotechnology 20 (50%)
- Medical 10 (25%)
- Medical Device 10 (25%)
- Health Diagnostics 6 (15%)
Stage
- Post-IPO Equity 9 (23%)
- Series C 8 (20%)
- Series D 7 (18%)
- Series B 4 (10%)
- Series E 4 (10%)
Country
- United States 22 (55%)
- Canada 3 (8%)
- Israel 2 (5%)
- Germany 1 (3%)
- The Netherlands 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Efrem Kamen
Founder and Managing Member
|
Founder and Managing Member | Total investments: 5 | Find email | |
|
Frank Litvack
Co-Founder Pura Vida Investments
|
Co-Founder Pura Vida Investments | Total investments: 1 | Find email | |
|
Frank Litvack
Co-Founder Pura Vida Investments
|
Co-Founder Pura Vida Investments | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Imperative Care
|
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $150M / Series E / Jul 25, 2024 | |
Alamar Biosciences
|
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California. | $128M / Series C / Feb 26, 2024 | |
Freenome
|
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M / Series E / Feb 15, 2024 | |
|
Freenome
|
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M / Series F / Feb 15, 2024 | |
Nalu Medical
|
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. | $85M / Series E / Jan 03, 2024 | |
Beta Bionics
|
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $100M / Series D / Aug 30, 2023 | |
Monogram Health
|
Monogram Health is derived from the monogram which is a sign of personal identity in the form of an individual’s or entity’s initial(s). They chose ‘monogram’ as it reflects the personalized focus of their service offerings, customizing each beneficiary’s plan of care to meet their individual goals and objectives in relation to their health statusand social determinants of health. Partnering with Health Plans and other Sponsors of Health Care, Monogram Health, through its Care Management and Coordination services portfolio is the collaboration catalyst with which individuals, their support systems, and providers achieve unparalleled health outcomes. | $375M / Series C / Jan 09, 2023 | |
Solid Biosciences
|
Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $75M / Post-IPO Equity / Sep 30, 2022 | |
Sonendo
|
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $63M / Post-IPO Equity / Sep 23, 2022 | |
Lyra Therapeutics
|
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently delivermedicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. | $100.5M / Post-IPO Equity / Apr 08, 2022 | |
| See all 40 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Pura Vida Investments invest in?
Pura Vida Investments invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity and Series C stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pura Vida Investments?
Public channels for Pura Vida Investments include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pura Vida Investments?
The team at Pura Vida Investments includes Efrem Kamen (Founder and Managing Member), Frank Litvack (Co-Founder Pura Vida Investments) and Frank Litvack (Co-Founder Pura Vida Investments). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
